Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity

This study assesses the lowest effective dose of intravitreous bevacizumab for severe retinopathy of prematurity.

Source: JAMA Ophthalmology - June 1, 2020 Category: Opthalmology Source Type: research